General Resources / Legal Resources / Medical
Resources / Briefing Papers / State Activity
Hospital Closures / Preventable
Tragedies / Press Room / Search
Our Site / Home
STATEMENT
By President E. Fuller Torrey, M.D.
PRINTABLE PDF VERSION OF THIS STATEMENTFor Immediate Release
Contact:
November 19, 2003
Alicia Aebersold 703-294-6008 or
[email protected]
NIMH Failure to Research Severe Mental
Illnesses
Both Federal Disgrace and Personal Tragedy
The National Institute of Mental
Health (NIMH) is grossly failing in its primary task of researching the causes and
treatment of serious mental illnesses. These illnesses, as defined by NIMHs advisory
council, consist of schizophrenia, bipolar disorder, autism, and severe forms of
depression, obsessive-compulsive disorder, and panic disorder. The sad truth is that NIMH
shows no interest in research on serious mental disorders, instead concentrating on
general research on human behavior and basic neuroscience. Much of this research is the
responsibility of, and is already being done by, other federal agencies.
In our present study of the 2002 NIMH
research awards, we found that only 28.5 percent of all research awards (1,187/4,157) had
any relationship to serious mental illnesses. Furthermore, only 5.8 percent (242/4,157) of
the awards were clinically relevant to serious mental illnesses, i.e., likely to improve
the treatment or quality of life for individuals currently affected with these diseases.
In other words, only 1 out of every 17 research grants currently funded by NIMH is likely
to help individuals who now have these diseases.
Equally disturbing is that during the
19972002 period in which the NIMH budget doubled from $661 million to $1.3 billion,
the proportion of NIMH awards for research on serious mental illnesses decreased. During
that period, NIMH rejected many research applications for the study of these illnesses but
funded many others unconnected to any mental disorder.
NIMH rejected funding for research on the causes of postpartum depression but funded research on the hearing mechanism of crickets.
NIMH rejected funding for research on why individuals with schizophrenia are unaware of their own illness, and there refuse to take medication, but funded research on communication among electric fish.
NIMH rejected funding for research on the side effects of antipsychotic and antidepressant medication in adolescents but funded research on how pigeons think.
NIMH rejected funding for a treatment trial to establish the most effective medication for individuals with a severe form of schizophrenia but funded research on how people in Papua New Guinea think.
The important question is not how people in Papua New Guinea think
but how officials at NIMH think. It is known that serious mental illnesses account for 58
percent of the direct care costs of all mental illnesses, yet NIMH allocates just over 28
percent of its research resources to these diseases. It is known that 5.6 million
Americans suffer from serious mental illnesses, and that on any given day approximately
250,000 of them are living on the streets or in jail because of their mental illnesses,
mostly untreated. It is known that serious mental illnesses cost the federal government
alone approximately $45 billion per year and that these costs have been rising at a rate
of $2.6 billion per year. From both a humanitarian and an economic point of view, the
failure of NIMH to do research on these diseases is irresponsible.
Imagine what the public would say if it was found that fewer than
one-third of all research awards from the National Cancer Institute (NCI) were going for
research on cancer. And that fewer than 6 percent of the awards1 out of 17were
likely to help anyone who today has cancer. That is the equivalent situation at NIMH
today.
NIMHs failure to do research on serious mental illnesses is not news within NIMH.
Last year, in fact, they undertook their own study to document the problem. We requested
access to this study under the Freedom of Information Act in May 2003, but to date NIMH
has refused to release it. Some preliminary data from this study that NIMH did make public
suggest that NIMHs failure to do research on serious mental illnesses is at least as
bad as we are reporting. In recent months, NIMH has implemented a few projects to improve
its research portfolio. However meritorious, these efforts are the equivalent of a
face-lift for a federal agency in need of a heart transplant.
We ask NIH Director Elias
Zerhouni, DHHS Secretary Tommy Thompson, the General Accounting Office, and Congress to
investigate this gross failure by NIMH to carry out its primary responsibility.
NIMHs refusal to do research on serious mental illnesses is not only a waste of
taxpayer funds, it is a federal disgrace and a personal tragedy for individuals affected
with these diseases.
###
The Treatment Advocacy Center (www.psychlaws.org) is a national nonprofit dedicated
to eliminating barriers to timely and humane treatment for millions of Americans with
severe mental illnesses. TAC is working on the national, state, and local levels to
educate civic, legal, criminal justice, and legislative communities on the benefits of
assisted treatment in an effort to decrease homelessness, jailings, suicide, violence and
other devastating consequences caused by lack of treatment.
general
resources | legal resources | medical
resources | briefing papers | state activity
hospital closures | preventable
tragedies | press room | search
| home
The contents of TAC's website are copyrighted by the Treatment Advocacy Center unless otherwise indicated. All rights reserved and content may be reproduced, downloaded, disseminated, or transferred, for single use, or by nonprofit organizations for educational purposes only, if correct attribution is made. TAC is an I.R.C. � 501(c)(3) tax-exempt corporation. Donations are appreciated and are eligible for the charitable contribution deduction under the provisions of I.R.C. � 170. Please note that TAC does not accept funding from pharmaceutical companies or entities involved in the sale, marketing, or distribution of such products. Treatment Advocacy Center (TAC), 200 N. Glebe Road, Suite 730, Arlington, VA 22203 703 294 6001/6002 (phone) | 703 294 6010 (fax) | www.treatmentadvocacycenter.org (website) [email protected] (general email) | [email protected] (press contact) [email protected] (webmaster) |